255 related articles for article (PubMed ID: 33723720)
1. WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.
Jin MH; Nam AR; Bang JH; Oh KS; Seo HR; Kim JM; Yoon J; Kim TY; Oh DY
Gastric Cancer; 2021 Sep; 24(5):1003-1020. PubMed ID: 33723720
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
4. WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
Sand A; Piacsek M; Donohoe DL; Duffin AT; Riddell GT; Sun C; Tang M; Rovin RA; Tjoe JA; Yin J
Cancer Lett; 2020 Mar; 472():119-131. PubMed ID: 31866466
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer.
Arienti C; Zanoni M; Pignatta S; Del Rio A; Carloni S; Tebaldi M; Tedaldi G; Tesei A
Oncotarget; 2016 Apr; 7(14):18424-39. PubMed ID: 26919099
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
Xing F; Gao H; Chen G; Sun L; Sun J; Qiao X; Xue J; Liu C
Mol Cancer; 2023 Jan; 22(1):6. PubMed ID: 36627608
[TBL] [Abstract][Full Text] [Related]
7. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
8. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
[TBL] [Abstract][Full Text] [Related]
9. HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Sampera A; Sánchez-Martín FJ; Arpí O; Visa L; Iglesias M; Menéndez S; Gaye É; Dalmases A; Clavé S; Gelabert-Baldrich M; Poulsen TT; Kragh M; Bellosillo B; Albanell J; Rovira A; Montagut C
Mol Cancer Ther; 2019 Nov; 18(11):2135-2145. PubMed ID: 31484705
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib sensitivities of two novel trastuzumab-resistant HER2 gene-amplified gastric cancer cell lines.
Oshima Y; Tanaka H; Murakami H; Ito Y; Furuya T; Kondo E; Kodera Y; Nakanishi H
Gastric Cancer; 2014; 17(3):450-62. PubMed ID: 23948998
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
[TBL] [Abstract][Full Text] [Related]
13. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.
Loi S; Giobbie-Hurder A; Gombos A; Bachelot T; Hui R; Curigliano G; Campone M; Biganzoli L; Bonnefoi H; Jerusalem G; Bartsch R; Rabaglio-Poretti M; Kammler R; Maibach R; Smyth MJ; Di Leo A; Colleoni M; Viale G; Regan MM; André F;
Lancet Oncol; 2019 Mar; 20(3):371-382. PubMed ID: 30765258
[TBL] [Abstract][Full Text] [Related]
15. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
16. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
[TBL] [Abstract][Full Text] [Related]
17. Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer.
Park J; Kang SK; Kwon WS; Jeong I; Kim TS; Yu SY; Cho SW; Chung HC; Rha SY
Sci Rep; 2023 Dec; 13(1):22648. PubMed ID: 38114573
[TBL] [Abstract][Full Text] [Related]
18. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
19. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
